Ionis Pharmaceuticals stock tumbled sharply in pre-market trading, falling about 13.1% to $50.51 as investors digested the implications of a pivotal clinical setback. The move followed Novartis' announcement that pelacarsen - an RNA-targeted cardiovascular therapy co-developed with Ionis - failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON trial.
The Lp(a)HORIZON study enrolled more than 8,300 high-risk patients over roughly six years and compared pelacarsen to placebo on a composite endpoint that included cardiovascular death, heart attack, stroke, and urgent coronary revascularization. While pelacarsen succeeded in lowering lipoprotein(a) concentrations in treated patients, that biomarker improvement did not translate into a statistically meaningful reduction in the trial's hard clinical outcomes.
The trial result raises fundamental questions about the therapeutic premise behind the Lp(a)-lowering drug class, because the expected correlation between Lp(a) reduction and fewer major cardiovascular events was not observed in this large, long-running investigation.
Financially, the implications for Ionis are direct and material. Under the companies' 2019 licensing agreement, Ionis was due tiered royalties on net sales in the mid-teens to low-20% range, together with up to $650 million tied to development, regulatory, and commercial milestones. With pelacarsen's commercial prospects effectively extinguished by the Lp(a)HORIZON outcome, those future revenues and milestones are now effectively eliminated for the program.
Analysts reacted to the news with differing tones. A team at Citi acknowledged the clinical setback but suggested that any immediate downside for Ionis could be limited because the company has a broader development portfolio. Another analyst kept a Buy rating on the stock and maintained a $100 price target, describing the Lp(a)HORIZON miss as a contained blow rather than a company-defining failure.
Market-wide conditions offered little support for Ionis as the stock fell. The S&P 500 was trading down about 0.2%, the Dow Jones Industrial Average was off roughly 0.7%, and the Nasdaq Composite was marginally positive near 0.1% - an environment that did not provide a meaningful offset to the company-specific selling pressure.
The pelacarsen setback compounds an already difficult period for Ionis. In July 2026 the company endured a steep sell-off after eplontersen failed in a separate cardiovascular Phase 3 trial, leaving the stock trading substantially below its 52-week high of $86.74. With pelacarsen's commercial value now erased and lingering uncertainty from the prior eplontersen result, Ionis shares moved toward their 52-week low of $50.01 in pre-market activity.
Despite the near-term pressures, Ionis does have recent and upcoming potential offsets within its pipeline. The company recently received approval for ZANVASTRO and is approaching a PDUFA decision for zilganersen on September 22, factors that analysts cite as partial support for the longer-term outlook but that did not prevent today's heavy selling.
Clear summary
Ionis shares plunged after the Phase 3 Lp(a)HORIZON trial for pelacarsen failed to show a statistically significant reduction in major cardiovascular events despite lowering Lp(a) levels. The outcome removes expected commercial revenue and milestone payments for Ionis under the 2019 licensing agreement and adds to prior trial disappointments, pressuring the stock toward its 52-week low.
Key points
- Pelacarsen's Phase 3 Lp(a)HORIZON study, involving more than 8,300 high-risk patients over six years, failed to reduce a composite of cardiovascular death, heart attack, stroke, and urgent coronary revascularization versus placebo.
- Although pelacarsen lowered lipoprotein(a) levels, that biomarker change did not produce a statistically meaningful improvement in clinical outcomes.
- Under the 2019 licensing deal, Ionis stood to receive mid-teens to low-20% tiered royalties and up to $650 million in milestones - now effectively eliminated for the commercial phase of pelacarsen.
- Market context offered little relief, with major U.S. indices mixed to lower on the session, and the stock moved near its 52-week low amid compounded program setbacks.
Risks and uncertainties
- Clinical uncertainty for the Lp(a)-lowering drug class following the Lp(a)HORIZON failure, which may affect investor confidence in related cardiovascular programs - primarily impacting biotech and pharmaceutical sectors.
- Loss of expected commercial revenue and milestone payments tied to pelacarsen under Ionis' licensing arrangement, creating financial headwinds for company valuation and near-term cash flow expectations - affecting investors and equity markets.
- Lingering effects from the earlier eplontersen Phase 3 failure in July 2026, which, together with the pelacarsen outcome, increase program risk and heighten stock volatility for Ionis.